Hanx Biopharmaceuticals (Wuhan) Co Ltd

03378

Company Profile

  • Business description

    Hanx Biopharmaceuticals (Wuhan) Co Ltd is a biotech company with in-house capabilities in structural biology, translational medicine, and clinical development, focused on developing immunotherapeutic products. Its product pipeline comprises one Core Product and nine other pipeline candidates: three clinical-stage drug candidates focused on oncology, including its Core Product HX009 and Key Products HX301 and HX044; and seven preclinical-stage drug candidates, including an antibody drug conjugate, a bispecific antibody, and a monoclonal antibody for both autoimmune and oncology markets.

  • Contact

    No. 1 Jiufeng 1st Road
    Building A8, Phase II, Bio-Innovation Park
    East Lake New Technology Development Zone
    Hubei
    Wuhan
    CHN

    T: +86 2765524978

    http://www.hanxbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    55

Stocks News & Analysis

stocks

Cheap ASX share may have more room to run

Shares are cheap despite rebounding share price, yet risks remain.
stocks

ASX listed media giant drives strong earnings growth

Digital growth drives earnings beat for media share.
stocks

ASX real estate platform outperforms yet questions remain

Valuation remains a key concern despite strong August reporting.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,424.1013.30-0.14%
CAC 408,726.0311.100.13%
DAX 4026,355.0735.620.14%
Dow JONES (US)53,968.2668.67-0.13%
FTSE 10010,862.5038.59-0.35%
HKSE25,937.49269.461.05%
NASDAQ26,640.6849.94-0.19%
Nikkei 22566,970.221,363.512.08%
NZX 50 Index13,888.2464.110.46%
S&P 5007,761.654.010.05%
S&P/ASX 2009,232.6017.00-0.18%
SSE Composite Index3,966.5926.560.67%

Market Movers